This invention is a human monoclonal antibody fragment (Fab) discovered utilizing phage display technology.  It is described in Crowe et al., Proc Natl Acad Sci USA. 1994 Feb 15;91(4):1386-1390 (PubMed abs) and Barbas et al., Proc Natl Acad Sci USA. 1992 Nov 1;89(21):10164-10168 (PubMed abs).  This MAb binds an epitope on the RSV F glycoprotein at amino acid 266 with an affinity of approximately 10⁹M^-1.  This MAb neutralized each of 10 subgroup A and 9 subgroup B RSV strains with high efficiency.  It was effective in reducing the amount of RSV in lungs of RSV-infected cotton rats 24 hours after treatment, and successive treatments caused an even greater reduction in the amount of RSV detected. 

Applications:

Research and drug development for treatment of respiratory syncytial virus

·     U.S. Patent 5,762,905 issued 09 Jun 1998 (HHS Reference No. E-032-1993/1-US-01)

·     U.S. Patent 6,685,942 issued 03 Feb 2004 (HHS Reference No. E-032-1993/1-US-02)

·     U.S. Patent Application No. 10/768,952 filed 29 Jan 2004 (HHS Reference No. E-032-1993/1-US-03)

Inventors:

Robert M. Chanock (NIAID), Brian R. Murphy (NIAID), James E. Crowe Jr. (NIAID), et al.

Licensees Sought:

Available for non-exclusive licensing.